Breaking News

Fujifilm Diosynth Biotechnologies Launches First Phase of Expansion in Denmark

First phase adds six mammalian cell bioreactors, bringing the total capacity at the Hillerød site to 12 x 20,000 L bioreactors.

Author Image

By: Charlie Sternberg

Associate Editor

Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) focused on biologics, vaccines, advanced therapies, and oncolytic viruses, has launched the first phase of its expansion at the Hillerød, Denmark site, bringing the new production capacity into operation.   This milestone marks the initial step in the company’s strategy to build a comprehensive global ecosystem dedicated to enhancing the production and delivery of medicines.   This first phase add...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters